Cerity Partners LLC Has $42.50 Million Holdings in Bristol Myers Squibb Company $BMY

Cerity Partners LLC grew its position in Bristol Myers Squibb Company (NYSE:BMY) by 9.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 942,270 shares of the biopharmaceutical company’s stock after acquiring an additional 79,647 shares during the quarter. Cerity Partners LLC’s holdings in Bristol Myers Squibb were worth $42,496,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. Exchange Capital Management Inc. increased its holdings in shares of Bristol Myers Squibb by 0.4% in the second quarter. Exchange Capital Management Inc. now owns 54,893 shares of the biopharmaceutical company’s stock valued at $2,541,000 after purchasing an additional 220 shares in the last quarter. Parsons Capital Management Inc. RI raised its stake in shares of Bristol Myers Squibb by 0.3% during the second quarter. Parsons Capital Management Inc. RI now owns 78,105 shares of the biopharmaceutical company’s stock worth $3,615,000 after buying an additional 224 shares during the last quarter. Richwood Investment Advisors LLC boosted its position in shares of Bristol Myers Squibb by 1.7% in the 2nd quarter. Richwood Investment Advisors LLC now owns 13,303 shares of the biopharmaceutical company’s stock worth $616,000 after purchasing an additional 225 shares during the last quarter. CBIZ Investment Advisory Services LLC boosted its holdings in Bristol Myers Squibb by 66.0% during the first quarter. CBIZ Investment Advisory Services LLC now owns 581 shares of the biopharmaceutical company’s stock worth $35,000 after buying an additional 231 shares during the last quarter. Finally, Mccarter Private Wealth Services LLC grew its holdings in Bristol Myers Squibb by 5.0% during the third quarter. Mccarter Private Wealth Services LLC now owns 4,931 shares of the biopharmaceutical company’s stock valued at $222,000 after purchasing an additional 235 shares during the period. Institutional investors own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $56.69 on Thursday. The stock has a market cap of $115.40 billion, a PE ratio of 19.15, a P/E/G ratio of 9.05 and a beta of 0.29. The company has a debt-to-equity ratio of 2.39, a quick ratio of 1.17 and a current ratio of 1.27. The firm has a 50-day moving average of $50.52 and a 200-day moving average of $47.68. Bristol Myers Squibb Company has a 52-week low of $42.52 and a 52-week high of $63.33.

Bristol Myers Squibb (NYSE:BMY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $1.63 EPS for the quarter, beating analysts’ consensus estimates of $1.52 by $0.11. The business had revenue of $12.22 billion for the quarter, compared to analyst estimates of $11.75 billion. Bristol Myers Squibb had a net margin of 12.57% and a return on equity of 76.53%. Bristol Myers Squibb’s quarterly revenue was up 2.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $1.80 EPS. Bristol Myers Squibb has set its FY 2025 guidance at 6.400-6.600 EPS. On average, sell-side analysts anticipate that Bristol Myers Squibb Company will post 6.74 EPS for the current year.

Bristol Myers Squibb Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, February 2nd. Investors of record on Friday, January 2nd will be issued a dividend of $0.63 per share. This represents a $2.52 annualized dividend and a yield of 4.4%. The ex-dividend date of this dividend is Friday, January 2nd. This is an increase from Bristol Myers Squibb’s previous quarterly dividend of $0.62. Bristol Myers Squibb’s payout ratio is 85.14%.

Analysts Set New Price Targets

Several research firms recently commented on BMY. Bank of America raised shares of Bristol Myers Squibb from a “neutral” rating to a “buy” rating and upped their target price for the stock from $52.00 to $61.00 in a research note on Monday, December 15th. Weiss Ratings reissued a “hold (c-)” rating on shares of Bristol Myers Squibb in a report on Tuesday, October 14th. Sanford C. Bernstein restated a “market perform” rating on shares of Bristol Myers Squibb in a report on Monday, November 3rd. Wells Fargo & Company increased their price target on shares of Bristol Myers Squibb from $53.00 to $55.00 and gave the company an “equal weight” rating in a research note on Wednesday, December 10th. Finally, Guggenheim restated a “buy” rating on shares of Bristol Myers Squibb in a research note on Tuesday, December 23rd. Six research analysts have rated the stock with a Buy rating, thirteen have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $56.08.

Trending Headlines about Bristol Myers Squibb

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: UBS upgraded BMY from Neutral to Buy and raised its price target to $65 (from $46), signaling stronger analyst conviction that BMY’s outlook and valuation are attractive — a clear near-term bullish catalyst for the stock. Bristol-Myers just upgraded at UBS — here’s why
• Positive Sentiment: Real‑world lung cancer data reported for nivolumab (Opdivo) adds evidence for continued demand in that indication, supporting BMY’s oncology revenue outlook and reducing execution risk around the immuno‑oncology franchise. Real-World Lung Cancer Study Adds Support for Nivolumab Growth Story
• Positive Sentiment: BMS quietly opened a first‑in‑human study for BMS‑986521, expanding the pipeline and giving investors a new clinical readout to watch for longer‑term upside beyond legacy products. Quietly Expands Pipeline With New First-in-Human Study of BMS-986521
• Positive Sentiment: Analyst and media commentary (Zacks, Motley Fool) point to BMY’s history of earnings beats, attractive dividend yield and FY25 guidance (6.40–6.60 EPS), which supports expectations for another upside surprise. Why Bristol Myers (BMY) is Poised to Beat Earnings Estimates Again Fat dividend and a chance for growth
• Neutral Sentiment: General market screens and sector stories (Zacks roundup pieces) include BMY as a medical stock to watch, but these are broader thematic notes rather than company‑specific catalysts. Why Investors Need to Take Advantage of These 2 Medical Stocks Now
• Neutral Sentiment: Articles highlighting BMY’s strong return on equity and financial metrics provide context on quality but are not immediate price drivers. Is Bristol-Myers Squibb Company’s (NYSE:BMY) 33% ROE Better Than Average?
• Negative Sentiment: Valuation concerns tied to patent cliffs for Opdivo and Eliquis are being raised — some pieces argue current pricing may not fully reflect near‑term generic/competitive risk, which is a material downward pressure on longer‑term revenue forecasts if realized. Is Bristol Myers Squibb (BMY) Pricing Reflect Recent Opdivo And Eliquis Patent Cliff Risks

Bristol Myers Squibb Company Profile

Bristol Myers Squibb is a global biopharmaceutical company headquartered in Princeton, New Jersey, focused on discovering, developing and delivering medicines for serious diseases. The company’s core activities include research and development, clinical development, manufacturing and commercialization of prescription pharmaceuticals across multiple therapeutic areas. BMS concentrates on advancing therapies in oncology, hematology, immunology, cardiovascular disease and specialty areas through both small molecules and biologics.

BMS’s marketed portfolio and late‑stage pipeline reflect a strong emphasis on cancer and immune‑mediated conditions.